Application of Intrahepatic Arterial Infusion Chemotherapy for Patients With High Risk of Liver Metastases After Pancreatic Cancer Surgery

NCT ID: NCT03687853

Last Updated: 2018-09-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-01-01

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Clinical results on intra-arterial adjuvant chemotherapy for prevention

of liver metastasis following curative resection of pancreatic cancer

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this study, the investigator try to select 80 patients who received radical surgery for pancreatic cancer, whose circulating tumor cells(CTCs) count then performed on intraoperative portal venous blood to predict postoperative liver metastasis and were divided into two groups. for those who have high CTCs count may have more chance for the occurrence of postoperative liver metastasis was applied hepatic arterial perfusion chemotherapy with minimal dynamic randomization. The aim is to evaluate the feasibility of hepatic arterial infusion chemotherapy for the prevention of postoperative liver metastasis and improvement of prognosis of pancreatic cancer, so as to further improve postoperative management of pancreatic cancer

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Ductal Adenocarcinoma Who Have High CTCs Count in Portal Venous Blood Liver Metastases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Pancreatic cancer patients who received hepatic arterial perfusion chemotherapy after operation
Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants
Pancreatic cancer patients who received chemotherapy through peripheral vein after operation

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intrahepatic Arterial Infusion chemotherapy

chemotherapy through intrahepatic arterial Infusion is one of the most widely used liver tumor treatments.

Group Type EXPERIMENTAL

Intrahepatic Arterial Infusion

Intervention Type DEVICE

Intrahepatic Arterial Infusion chemotherapy is one of the most widely used liver tumor treatments.

control

chemotherapy through Peripheral venous is one of the regularly used method.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intrahepatic Arterial Infusion

Intrahepatic Arterial Infusion chemotherapy is one of the most widely used liver tumor treatments.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* pancreatic cancer patients who received the radical operation

Exclusion Criteria

* who accepted chemotherapy before operation or who cannot or do not will to accepted enrolled into this study
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Peking University Third Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

dianrong xiu, doctor

Role: STUDY_CHAIR

Peking University Third Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of General Surgery,Peking University Third Hospital

Beijing, Beijing Municipality, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HAI PDCA 1.0

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Bioinformation Therapy for Pancreatic Cancer
NCT03239184 COMPLETED PHASE2/PHASE3